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MaThe recent discovery of human-induced pluripotent stem cells (iPSC) has revolutionized the ﬁeld of stem cells. iPSC have
demonstrated that biological development is not an irreversible process and that mature adult somatic cells can be
induced to become pluripotent. This breakthrough is projected to advance our current understanding of many disease
processes and revolutionize the approach to effective therapeutics. Despite the great promise of iPSC, many translational
challenges still remain. The authors review the basic concept of induction of pluripotency as a novel approach
to understand cardiac regeneration, cardiovascular disease modeling, and drug discovery. They critically reﬂect
on the current results of pre-clinical and clinical studies using iPSC for these applications with appropriate
emphasis on the challenges facing clinical translation. (J Am Coll Cardiol Basic Trans Science 2016;1:510–23) © 2016 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ORIGIN OF THE INDUCED
PLURIPOTENT STEM CELLS
The totipotency of a fertilized egg confers a unique
ability to divide and differentiate into all tissue types
to form an entire organism. To identify the exact role
of a mammalian cell nucleus undergoing embryonic
development, somatic cell nuclear transfer experi-
ments were conducted in frogs in the 1950s (1). These
experiments offered a proof of principle that plurip-
otency can be conferred to somatic cells by trans-
ferring their nuclear contents into oocytes (2). In fact,
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AB BR E V I A T I O N S
AND ACRONYM S
ESC = embryonic stem cell(s)
iCM = induced pluripotent stem
cell–derived cardiomyocyte(s)
iEC = induced pluripotent stem
cell–derived endothelial cell(s)
iPSC = induced pluripotent
stem cell(s)
MI = myocardial infarction
SCID = severe combined
nodeﬁcient
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511generated human iPSC from human dermal ﬁbroblasts
using retroviral transduction with the same 4 tran-
scription factors (8). These iPSC have morphology, cell
surface markers, and genes characteristics similar to
human ESC, exhibiting unlimited replication potential
without telomere shortening or karyotype changes.
The multilineage differentiation potential of iPSC has
been conﬁrmed both in vitro in embryoid bodies and
in vivo based upon teratoma formation upon injection
into severe combined immunodeﬁcient (SCID) mice.
Other groups reproduced the “stemness” or induced
pluripotency of somatic cells using the same or slightly
different transcription factors, demonstrating the
robustness of this technique and revolutionizing the
ﬁeld of stem cell biology (9–11).
Since the ability to generate iPSC in culture from
adult human skin ﬁbroblasts has been established
(8,9), this pluripotent state has been induced in a
variety of human cells including keratinocytes (12),
T-lymphocytes (13), peripheral mononuclear blood
cells (14), cord blood (15), placenta (16), neural stem
cells (17), adipose tissue (18), and renal epithelial cells
present in urine samples (19). Ectopic expression of
different combinations of reprogramming factors has
been used, with Oct4 being the most consistent across
protocols. Furthermore, several protocols have been
developed for directed in vitro differentiation of iPSC
into spontaneously contractile cardiomyocytes,
smooth muscle cells, and vascular endothelial cells
(20,21). The differentiation of iPSC into car-
diomyocytes was conﬁrmed by microscopic exami-
nation of beating colonies, immunostaining for
cardiac proteins, electrophysiological testing, and
real-time polymerase chain reaction analysis of car-
diac markers (20,21) (Figures 1A to 1C). The iPSC
overcame the ethical concerns and immunogenicity
of human ESC, thus becoming an attractive alternative
for autologous tissue repair and regeneration as well
as a source for allogeneic transplantation. The thera-
peutic potential of iPSC-derived cells has been tested
in many pre-clinical studies with some encouraging
results in murine and porcine models of myocardial
infarction (MI) (16,22–25). Currently, the ﬁrst human
trials of iPSC-derived cells, aimed at establishing
the safety of these cells, are enrolling patients with
age-related macular degeneration in Japan (26).
Beyond the potential for regenerative or trans-
plantation therapies, iPSC offer an unprecedented
opportunity to recapitulate both normal and patho-
logic human tissue formation in vitro, thereby
providing novel cell-based biological models that
enable better understanding of disease pathogenesis
and drug discovery (27). From 2008 to 2015, more than
70 human iPSC-based disease models have beenpublished in an exponential fashion (28). The
ability to examine the direct effects and
toxicity of newdrugs on the patients’ own cells
could also represent an invaluable tool for
drug development and discovery. For these
reasons, both Sir John Gurdon, who performed
nuclear transfer experiments, and Shinya
Yamanaka were awarded the Nobel Prize in
Physiology or Medicine in 2012. This review
discusses the current status of the cardiovas-
cular applications of iPSC for cardiac and
vascular regeneration, disease modeling, and
drugdiscoverieswith a special emphasis on the current
challenges for clinical translation (Figure 1).
iPSC FOR
CARDIOVASCULAR REGENERATION
With the growing epidemic of heart failure, cardiac
regeneration represents a major priority of regenera-
tive medicine. The ability of iPSC to differentiate into
autologous tissue-speciﬁc cells, similar to ESC but
without the need to destroy a human embryo, is an
important breakthrough in human stem cell biology.
A number of pre-clinical studies have explored the
effects of intramyocardial injection of induced
pluripotent stem cell–derived cardiomyocytes (iCM)
into murine and porcine models of MI (a complete
recent list of pre-clinical studies is provided in Lalit
et al. [29]). Nelson et al. (30) were the ﬁrst to perform
intramyocardial injection of iPSC-derived cells into a
murine model of acute MI. They found improved left
ventricular ejection fraction, fractional shortening,
and regional wall motion on echocardiography 4
weeks after permanent coronary artery ligation when
compared with the ﬁbroblast-injected animals.
Interestingly, they reported teratoma formation upon
subcutaneous and intramyocardial injections of iPSC
in immunodeﬁcient animals but none in immuno-
competent mice (30).
Other studies have reported formation of intra-
mural teratomas in both immunocompetent and SCID
mice after intramyocardial injection of undifferenti-
ated iPSC (31,32). Kim et al. (32) tracked the engraft-
ment of iPSC at 4 weeks in a SCID murine model of MI.
They demonstrated teratoma formation with no
myocardial or endothelial cell differentiation despite
the reported improvement in myocardial function
and myocardial viability (32). This demonstrates a
potential mechanistic role of cytokines released from
the iPSC, which may restore cardiac function despite
teratoma formation. Similar results were obtained
with undifferentiated iPSC in a rat model of MI (33),
which is consistent with the initial studies of
immu
FIGURE 1 The Cardiovascular Applications and Characteristics of iPSC-Derived Cardiomyocytes
(A) Immunostain of induced pluripotent stem cell (iPSC)-derived cardiomyocytes in cell culture demonstrate striated pattern of cardiac
troponin T, a-actinin, connexin 43, and deoxyribonucleic acid (DNA). (B) Calcium metabolism and atomic force microscopy demonstrate live-
cell calcium imaging of the contractile iPSC–derived cardiomyocytes, exhibiting regular and synchronous Ca2þ transients (left) with each
contractile activity (right). (C) Histogram of atomic force microscopy evaluates the force exerted by each contraction of a representative iPSC-
derived cardiomyocytes. The maximal contractile force measured for 4 representative beating cells was comparable to that of native
cardiomyocytes (150 to w550 pN).
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toma formation (34,35).
Repeat experiments using differentiated skeletal
myoblast derived-iCM obtained from day 10 embryoid
body–beating aggregates reported improved cardiac
function with decreased infarct size and no evidence
of tumorigenesis (36). Similar improvement in left
ventricular function without teratoma formation was
reported by the same group using cardiac progenitors
harvested from embryoid body–beating aggregates
of mesenchymal stem cells’ derived-iPSC (37).
Currently, it is widely thought that the pluripotent
stem cell derivatives from either ESC or iPSC are
still premature for clinical therapy because of the
tumorigenic potential. Active research is ongoing
using highly puriﬁed monolayer populations ofdifferentiated iCM and methods to remove the un-
differentiated iPSC (38). Through these efforts, the
generation of >90% pure populations of iCM is
increasingly routine in laboratories worldwide (39).
Using a single transcription factor (Oct3/4), Pasha
et al were able to generate iPSC from mouse skeletal
myoblasts that endogenously express 3 of the Yama-
naka factors (40). They were also able to isolate car-
diac progenitors from 5-day beating embryoid bodies.
In this experiment, iPSC-derived cardiac progenitor
cells showed sustained engraftment and gap junction
formation upon transplantation into the infarcted
murine heart (40). Another group reported signiﬁ-
cantly restored cardiac function in post-MI ventricu-
lar remodeling after intramyocardial injection of
fetal-liver kinase 1–positive iPSC-derived cardiac
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 6 , 2 0 1 6 Youssef et al.
O C T O B E R 2 0 1 6 : 5 1 0 – 2 3 Cardiovascular Application of iPSC
513progenitor cells into SCID mice (41). Based on the
advantage conferred by epigenetic memory, cardiac
progenitor cells expressing the surface marker Sca1
were used for induction of pluripotency to leverage
their preferential cardiac differentiation potential.
Compared with skin ﬁbroblast-derived iPSC, cardiac
progenitor cell–derived iPSC were more efﬁcient in
producing cardiomyocytes, smooth muscles cells, and
endothelial cells (25). However, in vivo echocardiog-
raphy and post-mortem infarct size analysis showed
no signiﬁcant difference between the 2 types of cells
that were only marginally better than placebo at 8
weeks (25).
To improve the engraftment of iCM into the
infarcted myocardium, Dai et al. (42) developed a
homologous peritoneal patch seeded with iCM, CD31-
selected iPSC-derived endothelial cells, and mouse
embryonic ﬁbroblasts (tri-cell patch). The tri-cell
patch was used to cover the infarcted area instead
of an intramyocardial injection into an infarcted
myocardium (42,43). Kawamura et al. (22) used a cell-
sheet technique to ensure delivery of a large number
of cells. Immunosuppressed minipigs (n ¼ 6) were
transplanted with human iCM in cell sheets, con-
taining approximately 25 million cells, 4 weeks after
MI. Signiﬁcantly improved left ventricular ejection
fraction and reduced end-systolic volume were noted
in the iCM group. Despite these positive results over
sham pigs, poor engraftment was noted by 8 weeks.
The investigators proposed that the poor engraftment
was due to insufﬁcient immune suppression with a
single agent (tacrolimus) in a xenogeneic trans-
plantation model (22).
Beyond myocardial regeneration, many in-
vestigators have employed iPSC technology for
inducing vascular regeneration in patients with cor-
onary and peripheral artery disease where new
vascular structures might overcome impaired perfu-
sion caused by occlusive atherosclerotic disease. Most
work in vascular regeneration has been done with
adult stem cells (44). For peripheral artery disease,
smaller clinical trials of adult stem cell therapy have
shown promise in populations with different levels of
disease severity (45,46). Currently, a large National
Institutes of Health/National Heart, Lung, and Blood
Institute–sponsored Cardiovascular Cell Therapy
Research Network trial using aldehyde dehydroge-
nase bright cells for intermittent claudication is
ongoing (47). Stem cells obtained from adult tissues
can be problematic, however. In elderly patients and
those with comorbidities such as diabetes—the pa-
tients most likely to beneﬁt from stem cell therapy—
the quantity and function of stem cells can be
impaired (48,49). In contrast, iPSC can theoreticallybe derived from many tissue sources, thereby obvi-
ating the issue of cell quantity and quality. Further-
more, due to their pluripotency, iPSC can
differentiate into the multiple cell types needed in
ischemic tissue such as smooth muscle, pericyte, and
cardiac cells in addition to the endothelial cells for
regenerative purpose (30).
Although there are currently no clinical trials using
iPSC for neovascularization, pre-clinical studies show
great promise (50). Choi et al. (51) and Taura et al. (52)
were among the ﬁrst researchers to describe differ-
entiation of iPSC into endothelial cells. Both groups
found that the induced pluripotent stem cell–derived
endothelial cells (iEC) were very similar to endothe-
lial cells derived from human ESC. Since then, the iEC
have been used in murine hindlimb ischemia models
and have been found to improve limb perfusion at
least in part through neovascularization. Compared
with the human ESC, iEC appear to have similar ther-
apeutic efﬁcacy (53). Another potential use of the iEC
in the setting of vascular insufﬁciency is for engi-
neering better vascular conduits. Wang et al. (54) have
demonstrated that functional smooth muscle cells
can be derived from human iPSC and used on a scaf-
fold to regenerate vascular tissue in vivo. Additional
pre-clinical studies will demonstrate the potential
efﬁcacy of these novel therapeutic approaches.
CURRENT CHALLENGES FOR THE iPSC IN
CARDIOVASCULAR REGENERATION
Despite the promise of iPSC for regenerative medi-
cine, there are still many roadblocks remaining that
may hinder their clinical use.
CELL ENGRAFTMENT. Poor cell engraftment remains
a major challenge for all stem cell therapies for car-
diovascular applications. The inability of the trans-
planted cells to exhibit long-term survival and
engraftment into the host myocardium with suc-
cessful electromechanical integration into the com-
plex cardiac syncytium has been a consistent ﬁnding
throughout many studies (55–58). Despite the fast
pace of progress in the ﬁeld of stem cell biology, there
has been no improvement in engraftment over the
past decade regardless of the types of stem cells used
(25,57,59,60). In many pre-clinical studies with posi-
tive functional results, the assessment of long-term,
stable engraftment and electromechanical integra-
tion of the stem cells by the use of molecular reporter
genes has yielded variable results (32,59). In most of
these studies, the mechanism underlying the positive
results was postulated to be a “paracrine effect”
(22,32,58). The shortcoming of the paracrine effect
hypothesis is that it is difﬁcult to measure this
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the speciﬁc biochemical factor(s) responsible for the
salubrious actions of stem cells. Nevertheless, in-
vestigations are in order because if such a paracrine
factor(s) is identiﬁed, this ﬁnding may obviate the
need for cell therapy.
To address questions regarding the magnitude and
mechanism of cardiac repair after injury in a practical
way, multiple animal and clinical studies have tested
the efﬁcacy of different stem cell types for cardiac
regeneration (58). Nevertheless, the limited engraft-
ment of the stem cells and the inability to track the
cells delivered in vivo have left many unanswered
questions regarding the mechanism and description
of the postulated beneﬁt.
Although no direct correlative data exist, the poor
cell engraftment may be associated with the low
regenerative capacity of the heart. Earlier studies in
late 1990s and early 2000s using evidence from small-
animal experiments (61), clinical sex-mismatched
heart and bone marrow transplantation studies (62),
and the observation of dividing myocytes within the
infarcted myocardium (63) and failing hearts (64)
showed that the heart may possess signiﬁcant
regenerative capacity, contradicting the old dogma of
the heart as a terminally differentiated organ. These
studies, together with the concomitant isolation of
different types of adult human stem cells (65,66) and
human ESC (67), established the foundation of the
emerging ﬁeld of regenerative cardiology. Despite the
optimism that accompanied these studies, the rate
and magnitude of ongoing turnover and cardiac
regeneration have been controversial, with more
recent studies showing that adult cardiomyocytes
may possess very limited mitotic capability (68,69).
Bergmann et al. (68) calculated the post-natal human
cardiomyocyte renewal at w1% annually at age 20,
declining to 0.4% annually by age 70. More recently,
van Berlo et al. (69) found that endogenous c-kitþ
cells mainly regenerate endothelial cells with only a
minor contribution toward cardiomyocyte renewal,
estimated at a rate of 0.03% to 0.008%.
Another reason for the low engraftment could be
the study design and route of administration of stem
cells. Most stem cell studies attempted to deliver stem
cells into an area of infarction, either directly through
intramyocardial injection or indirectly through intra-
coronary infusion, to regenerate the myocardium.
Such a design worked well with bone marrow trans-
plantation but may not be suitable for a complex organ
such as the heart, particularly in the setting of
ischemic cardiomyopathy with impaired perfusion,
increased oxidative stress, and inﬂammation. Even in
the skin, which is a regenerative organ, skin burns arenot cured by injecting stem cells into the skin but
rather by using skin grafts. It may be necessary to
modify current delivery techniques to address the
complexity of the heart. Efforts are underway by
several groups using different tissue-engineering
techniques and cell derivatives (22,42,43).
Cell engraftment in studies of vascular regenera-
tion poses a different challenge. In contrast to the low
regenerative capacity of cardiomyocytes, endothelial
cells show greater capacity for regeneration and
repair in response to vascular injury via endothelial
progenitor cells mostly derived from the bone
marrow (70,71). However, age and cardiovascular
diseases such as coronary artery disease, cerebral
vascular disease, congestive heart failure, and dia-
betes can signiﬁcantly reduce both the quality and
quantity of circulating endothelial progenitor cells.
Though studies evaluating the nature of iPSC
incorporation into native vascular endothelium are
lacking, using embryonically derived endothelial cells
(ESC-EC), Huang et al. (72) provided evidence of
stem cell engraftment and neovascularization in a
mouse ischemic limb model.
TECHNICAL ISSUES WITH THE INDUCTION OF
PLURIPOTENCY, CARDIAC DIFFERENTIATION, AND
MATURATION. Reprograming somatic cells to a
pluripotent state involves introducing transgenes,
their derivative ribonucleic acid, or protein products
with multiple passages in tissue culture. Several
studies suggest that the reprogramming process in-
duces genomic instability and down-regulates tumor
suppressor genes, which can affect cellular integrity
(73–76). Comparing 12 human iPSC lines generated
from the same primary ﬁbroblast cell, Laurent et al.
(76) found genetic aberrations in iPSC lines that were
not present in the original ﬁbroblast line. Also, Li
et al. (75) calculated the degree of genetic heteroge-
neity among 24 iPSC clones obtained from skin ﬁ-
broblasts of the same 8-week-old mouse and found
383 iPSC variants from the original 24 clones with a
mean of 16.0 variants/clone and a range of 0 to 45,
indicating a wide range of heterogeneity. For these
reasons, iPSC are not approved for clinical use in the
United States, and many have suggested that the
study in the Japanese patients with age-related
macular degeneration may be premature (77).
As the ﬁeld of iPSC is only few years old, protocols
for induction of pluripotency and cardiac differenti-
ation are still evolving and there is a lack of
consensus. Current iPSC lines have been generated
using different cells of origin, different transcription
factor combinations, different vectors (viral and
nonviral), different time in culture, different number
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515of passages, and different selection methods. Such
inconsistency adds further layers of complexity to the
endogenous heterogeneity created by the reprog-
ramming process and expansion in culture, resulting
in the absence of the uniformity needed for clinical
therapeutic applications.
Pluripotency can be induced from a variety of
human cells (12–19), and the best cell of origin for
induction of pluripotency for cardiac application is
not known yet. Several studies have suggested that
after induction of pluripotency, somatic cells retain
some characteristics of their past identity, the so-
called epigenetic memory (78). Although this epige-
netic memory can be seen as a sign of incomplete
programming, it can be used to facilitate differentia-
tion toward the desired cell type more efﬁciently (27).
Another technical issue is the low efﬁciency of the
reprogramming process, which ranges from as much
as 4.4% with modiﬁed messenger ribonucleic acid
and 1% with integrating viruses to as little as 0.001%
with the nonintegrating Sendai virus, adenovirus,
plasmids, and direct protein delivery (79). Efﬁciency
decreases further if one does not use the oncogene
c-myc (80). Currently, integrating viruses are falling
out of favor because of the oncogenic potential
resulting from incomplete proviral silencing. A recent
comprehensive analysis of nonintegrating reprog-
ramming methods for human iPSC was published to
compare the quality of cells, reliability, efﬁciency,
speed of colony emergence, aneuploidy rate, and
hands-on time for each method (81).
Optimized protocols for cardiac differentiation
have been developed that replicate the key commit-
ment stages found during embryonic development
(82). Whereas removal of the undifferentiated cells
and puriﬁcation of the iCM are becoming more stan-
dardized (83) (Figure 2), it is becoming evident that
the iCM may represent immature and heterogeneous
groups of cardiomyocytes (38,84). A recent study
calculated ventricular cardiomyocytes to be 50% of
differentiated cardiomyoctes, with atrial car-
diomyocytes being 37.5% and nodal cells 12.5% (85).
The clinical use of this mixture of different iCM again
may generate inconsistent results. A similar phe-
nomenon is seen in the production of human iPSC-EC
(iEC), which have been found to express multiple cell
markers associated with lymphatic, venous, and
arterial EC (86). In this study, higher levels of VEGF
were associated with more iEC with an arterial
phenotype and it was this arterial phenotype of cells
that demonstrated the best in vivo performance in the
development of mature and stable capillaries.
Cardiomyocyte maturation is another important
step for cell therapy. In vitro tissue culture conditionsare obviously different from the environment of
developing embryonic hearts. The tensile stretch
exerted on the developing cardiomyocytes as well as
the micro-environmental milieu of molecules and
growth factors play a key role in cardiomyocytes’
growth and maturation. The current cell culture tech-
niques on theﬂat surfaceof a petri dishor in suspension
deprive the developing cardiomyocytes of important
maturation signals. Newer culture techniques that
offer optimal tensile structure for the developing car-
diomyocytes, pulsed treatment with novel molecules
and growth factors, and electrophysiological cues
may enable selection of the iCM at a developmentally
appropriate stage for therapeutic purposes (87).
IMMUNOGENICITY. One advantage of iPSC over other
types of stem cells is their autologous source, with no
expected immune rejection. This assumption is also
supported by the lack of immune rejection upon
administration of iPSC in many pre-clinical studies.
However, a few studies have reported T-cell immune
rejection of undifferentiated iPSC upon trans-
plantation into syngeneic mice (88,89). These studies
raise the possibility that cell reprogramming, genetic
instability, culture conditions, and frequent passages
could alter iPSC in a way that renders them immuno-
genic. However, further studies using differentiated
iPSC have shown negligible immunogenicity (90,91).
Taken together, the available evidence indicates that
although immune rejectionmaybe possible, it does not
seem to be a consistent ﬁnding. The ongoing clinical
trial in age-related macular degeneration in Japan will
also address this question. However, we believe that
further pre-clinical studies using differentiated cells
are required to resolve the issue of immunogenicity.
AUTOLOGOUS VERSUS ALLOGENEIC SOURCE. One
great advantage of iPSC is the autologous source,
which makes iPSC an inexhaustible source for cell
therapies without immune rejection or ethical issues.
However, there are several logistic issues with an
autologous source. Induction of pluripotency fol-
lowed by lineage-speciﬁc differentiation is a time-
consuming process that requires multiple passages
of iPSC followed by differentiation and puriﬁcation,
which may make autologous iPSC suitable only for
chronic illnesses but not for acute conditions such as
acute MI. Also, custom-made autologous cells would
make clinical good manufacturing practice, quality
assurance, regulatory compliance, and elimination of
technical errors very expensive, limiting the repro-
ducibility of the technique and its potential
wide-scale clinical application (92). This paradigm,
however, applies to almost all autologous cell thera-
pies requiring in vitro expansion.
FIGURE 2 Flow Cytometry Analysis of iCM Purity
Cardiac troponin T (cTnT), vascular adhesion molecule-1 (VCAM1), and cTnT/VCAM1 double-positive cells demonstrate high purity of induced pluripotent stem cell–
derived cardiomyocytes (iCM). VCAM1 was shown to be a potent cell surface marker for robust, efﬁcient, and scalable puriﬁcation of cardiomyocytes from human
embryonic stem cells/human induced pluripotent stem cells (83). FSC ¼ forward-scattered light; LL ¼ lower left; Q5 ¼ human endothelial cells; UL ¼ upper left;
UR ¼ upper right; SSC ¼ side-scattered light.
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516Whereas iPSC are traditionally considered a po-
tential autologous therapy, the ability to identify iPSC
genotypes and preselect matching donors provides a
potential opportunity for allogeneic therapy. Several
investigators have proposed the creation of large
allogeneic libraries of clinical-grade quality iPSC and
iPSC-derivatives (92–94). However, such cell/tissue
libraries would require several thousand random do-
nors to cover the human leukocyte antigen genotype
variability within a speciﬁc population (94,95).
Despite logistic and ﬁnancial difﬁculties, establish-
ment of a blood-derived iPSC library has been initi-
ated in Japan (92). This approach would provide safe
off-the-shelf allografts of human leukocyte antigen–
homozygous iPSC-derivatives ready for clinical use
after excluding tumorigenic clones (96). Another
advantage of the iPSC library is that the donors will be
subjected to only minor procedures (e.g., blood
sampling, skin biopsy) whereas the iPSC can be used
in an unlimited number of matched recipients
(93), addressing the tissue availability issue and
potentially improving graft survival (97), but not
completely eliminating the need for immunosup-
pressive medications.
TUMORIGENICITY. Tumorigenicity represents another
potential obstacle to the clinical application of iPSC. In
fact, the current functional gold standard test for plu-
ripotency of human iPSC is teratoma formation uponinjection into immunodeﬁcient mice (7). Pluripotent
origin, incomplete differentiation, and difﬁculty in
eliminating all undifferentiated cells may lead to
potential teratoma formation (7). However, advances
in differentiation techniques and tissue culture con-
ditions have mitigated this challenge, resulting in
highly pure (>90%) iCM populations (38,39).
In addition to the potential for teratoma formation
by the undifferentiated cells, differentiated iPSC still
carry an intrinsic risk of malignant transformation
(98). The original use of retroviruses for induction of
pluripotency with integration into the host deoxy-
ribonucleic acid is a contributing factor. The over-
expression of oncogenes, such as c-Myc, used in the
original iPSC reprogramming protocol, carries another
uncertainty. This has led to modiﬁcations of the
original technique to induce pluripotency without
using retroviral vectors (81). The current use of the
ribonucleic acid nonintegrating modiﬁed Sendai virus
eliminates the potential risk of genomic integration
and maintains good transduction efﬁcacy (99).
FUTURE DIRECTIONS FOR
CARDIOVASCULAR REGENERATION
Despite the limited innate ability of the injured
myocardium and vasculature to regenerate, the
implementation of iCM and iEC holds promise for
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517regenerative medicine. Simpson et al. (100) suc-
ceeded in constructing a biologically active human
pulmonary valve from a decellularized valve that was
seeded with iPSC-derived mesenchymal stem cells.
Also, combining bioengineering technology with
iPSC-derivatives to construct engineered tissue may
be more effective than direct intramyocardial injec-
tion to limit infarct expansion and adverse remodel-
ing, leading to heart failure (22,42).
Direct reprogramming or transdifferentiation,
whereby terminally differentiated cells such as car-
diac ﬁbroblasts are changed into cardiomyocytes
without ﬁrst producing a pluripotent intermediate,
may be an alternative strategy. Transdifferentiation
has been known for decades. It was deﬁned by
Pritchard in 1978 as “the ability of a cell to lose a
deﬁnitive characteristic and to acquire another
feature characteristic of an alternate state” (quoted
in [101]). The advent of iPSC technology has revolu-
tionized the ﬁeld of transdifferentiation by demon-
strating that biological development is not an
irreversible process. The discovery demonstrated that
the individual cell function is largely dictated by
changes in gene expression within each individual
tissue or cell. Inspired by the experimental ﬁndings of
Takahashi and Yamanaka (6), Ieda et al. (102) tested
14 key transcription factors for early heart develop-
ment to reprogram ﬁbroblasts into cardiomyocyte-like
cells. They were able to convert mouse post-natal
cardiac or dermal ﬁbroblasts into functional beating
cardiomyocytes in vitro using a combination of 3
transcription factors—Gata4, Mef2c, and Tbx5 (102). In
2012, in vivo delivery of Gata4, Mef2c, and Tbx5
transcription factors using a gene therapy approach
converted mouse nonmyocytes into induced car-
diomyocytes with improved cardiac function and
reduced scar size after MI (103,104). Compared with
the in vitro induced cardiomyocytes, in vivo induced
cells appeared more similar to endogenous car-
diomyocytes, suggesting the importance of in vivo
environmental cues such as electromechanical stim-
ulation, signaling pathways, and extracellular matrix
(105). This approach appears promising but carries
signiﬁcant limitations, including low efﬁciency,
incomplete reprogramming, lack of robust experi-
mental reproducibility, and the use of retroviral vec-
tors in vivo (106). Greater understanding of the
epigenetic changes associated with direct reprogram-
ming is needed to enhance its therapeutic potential.
Similarly, Margariti et al. (107) have described
partial reprogramming of ﬁbroblasts directly into iEC
using Oct4, Sox2, Klf4, c-Myc, and endothelial cell-
speciﬁc media and culture conditions. These cells
were able to repopulate decellularized vesselscaffolds with appropriate vascular structure and
good attachment. However, this model still requires
viral transduction. Moving away from this approach
entirely, Lee et al. (108) have described the role of
innate immunity in nuclear reprogramming and have
gone on to demonstrate that using a toll-like receptor
3 agonist and exogenous endothelial cell growth fac-
tors, ﬁbroblasts can be induced into EC (109). When
transplanted into a murine ischemic hind limb model,
these EC led to neovascularization and improved limb
perfusion. Ultimately, safe, effective, and reproduc-
ible large-animal models will be necessary for even-
tual clinical translation.
iPSC FOR DISEASE MODELING AND
DRUG DISCOVERIES
iPSC have an emerging role in modeling human dis-
eases at the cellular level and in facilitating new drug
discoveries. Modeling of human diseases contributes
to our understanding of the underlying pathophysi-
ology, development of novel therapeutics, and eval-
uation of therapeutic efﬁcacy and toxicity. Currently
available disease models rely mainly on in vitro hu-
man cell lines and animal models for human diseases.
The inherent limitations of this paradigm have hin-
dered rapid advances in the understanding of many
disease processes and their subsequent treatment.
Similarly, multicenter clinical trials do not address
the interindividual genetic variations that will
necessitate larger numbers of participants with
resultant increased time and cost.
The introduction of human iPSC as a source of
in vitro disease models has added a new dimension to
the current biomedical research tools. Shortly after
the discovery of human iPSC, Park et al. (110) were
able to prepare disease-speciﬁc iPSC lines in culture
from patients with genetic disease, both with Men-
delian and complex inheritance. Modeling rare ge-
netic diseases such as long QT syndrome (111),
LEOPARD (Lentigines, Electrocardiographic conduc-
tion abnormalities, Ocular hypertelorism, Pulmonary
stenosis, Abnormalities of genitalia, Retardation of
growth, Deafness) syndrome (112), and familial
dilated cardiomyopathy (113) using patient-derived
iPSC provided a deeper insight into the molecular
mechanisms and signaling pathways responsible for
disease phenotype. Obtaining peripheral blood cells
or skin biopsy from patients with rare genetic heart
diseases enables researchers to model the disease
in vitro. The molecular mechanism of different dis-
eases can be thoroughly studied at an individual
cellular and genetic level in an unprecedented
manner. Integration of patient-derived iPSC with the
TABLE 1 Disease Models and Drug Testing Studies of Cardiovascular Disease
Mutation Aim Drug Tested Number First Author (Ref. #)
Supravalvular aortic
stenosis
ELN Modeling þ therapy Elastin recombinant
protein
2 patients
2 control subjects
Ge et al. (128)
Hypoplastic left
heart syndrome
N/A Modeling Isoproterenol 1 patient
1 control subject
Jiang et al. (116)
ARVD PKP2-2057del2 Therapy SB216763 2 patient
2 control subjects
Asimaki et al. (129)
ARVD PKP2 L614P Modeling N/A 1 patient
1 control subject
Ma et al. (130)
ARVD PKP2 c.2484C>T PKP2
c.2013delC
Modeling N/A 2 patients
2 control subjects
Kim et al. (131)
Familial dilated
cardiomyopathy
TNNT2-R173W point
mutation
Therapy Metoprolol 4 patients
3 control subjects*
Sun et al. (113)
Hypertrophic
cardiomyopathy
MYH7 Arg663His Modeling Verapamil,
Diltiazem
5 patients
5 control subjects*
Lan et al. (132)
LEOPARD syndrome PTPN11 T468M Modeling N/A 2 patients
2 control subjects
Carvajal-Vergara
et al. (112)
Fredrick ataxia FXN GAA triplet
repeat expansion
Modeling N/A 2 patients
2 control subjects
Hick et al. (133)
Pompe syndrome GAA Therapy rhGAA enzyme,
2-3-methyladenine,
3-L-carnitine
2 patients
2 control subjects
Huang et al. (134)
Barth syndrome TAZ c.517delG
TAZ c.328T>C
Modeling þ therapy TAZ modRNA 2 patients
3 control subjects*
Wang et al. (115)
CPVT RyR2 P2328S Modeling Adrenaline 1 patient
2 control subjects
Kujala et al. (135)
CPVT RyR2 S406L Therapy Dantrolene 1 patient
1 control subject
Jung et al. (136)
CPVT CASQ2 D307H Modeling Isoproterenol 2 patients*
3 control subjects
Novak et al. (137)
CPVT RyR2 M4109R Therapy Flecainide, Thapsigargin 1 patient
1 control subject
Itzhaki et al. (138)
LQT1 KCNQ1 R190Q
missense mutation
Modeling Propranolol,
Isoproterenol
2 patients
2 control subjects
Moretti et al. (111)
LQT2 KCNH2 A614V Therapy Nifedipine, Pinacidil,
Ranolazine, Cisapride,
IKr blocker E-4031
1 patient
1 control subject
Itzhaki et al. (139)
LQT2 KCNH2 R176W Modeling Sotalol 1 patients
3 control subjects
Lahti et al. (140)
LQT2 KCNH2 G1681A Therapy PD118057, Nicorandil,
ß-blocker
2 patients*
2 control subjects
Matsa et al. (141)
Timothy syndrome
(LQT8)
Calcium-channel
gene G1216A
Therapy Roscovitine 2 patients
2 control subjects
Yazawa et al. (142)
*Patients from the same family.
ARVD ¼ arrhythmogenic right ventricular dysplasia; CASQ2 ¼ calsequestrin 2; CPTV ¼ catecholaminergic polymorphic ventricular tachycardia; ELN ¼ elastin; FXN ¼ frataxin; LEOPARD ¼
Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormalities of genitalia, Retardation of growth, Deafness; LQT ¼ long QTc syndrome;
modRNA ¼ modiﬁed RNA; N/A ¼ not applicable; PKP2 ¼ plakophilin-2; PTPN ¼ protein-typrosine phosphatase nonreceptor; rhGAA ¼ recombinant acid alpha-glucosidase; RYR2 ¼ cardiac
ryanodine receptor; TAZ ¼ tafazzin.
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518advances in bioengineering such as the disease-on-
a-chip technology will take these models from an in-
dividual cell to the tissue level (114). With such
advances, modeling genetic mitochondrial cardio-
myopathy on a chip has become a reality (115).
With the development of successful cardiomyocyte
differentiation protocols, Moretti et al. (111) modeled
type 1 long QTc syndrome in vitro. They were able to
describe a dominant negative trafﬁcking defect that
causes prolonged action potential in ventricular and
atrial cardiomyocytes, which are exacerbated upon
exposure to catecholamines and attenuated withbeta-adrenergic blockers (111). The response to
isoprenaline and metoprolol further validates this
in vitro model as it correlates with the known effect of
these medications in long QTc syndrome patients.
iPSC-derived disease models not only include genetic
abnormalities but also structural heart diseases such
as the hypoplastic left heart syndrome (116). A full list
of iPSC-derived cardiovascular disease models is
shown in Table 1.
For drug testing, iPSC-derived disease models can
serve as an additional in vitro arm to augment phase
II and phase III clinical trials for dose optimization,
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519efﬁcacy, safety, side effects, and drug-drug interac-
tion (28). The signal is measured in terms of physio-
logic effects such as shortening of the action
potential duration, reduction in protein or gene
expression, enzymatic activity, cell proliferation,
apoptosis, or other measurable signal related to the
disease process (117). Testing a small number of
candidate drugs is an efﬁcient way to monitor their
therapeutic effects. Also, evaluating the effects of
hundreds of medical compounds on patient-speciﬁc
iPSC-derived cells in a systematic, less biased
manner is possible using high-throughput drug
screening systems (118). Lee et al. (118) tested the
effect of 6,912 compounds on human iPSC-derived
neural crest precursors. They found 8 compounds
capable of rescuing the gene responsible for familial
dysautonomia (118). Another big advantage of using
iPSC for disease modeling and drug discovery is the
very small number of patients needed to achieve
valid conclusions about disease mechanisms and
drug toxicity (Table 1). This will not preclude the
need for eventual clinical trials as the ﬁnal conﬁr-
matory step in drug discovery. However, the insights
gained from these models are expected to increase
the efﬁciency of the process by decreasing the need
for some of the lengthy animal research. Further-
more, the ability to predict a patient’s response may
enhance the trial design by shortening the duration
and reducing the cost of randomized clinical trials,
which may lead the transition to personalized
medicine.
Similarly, high-throughput screening systems for
drug discovery may be employed to investigate iPSC-
derivatives from different tissue types for toxicity
and side effects. Using iCM, Guo et al. (119) tested 88
drugs for in vitro arrythmogenicity potential.
Navarette et al. (120) developed an in vitro system to
screen for drug-induced arrhythmia using iCM from a
skin biopsy of a 14-year-old volunteer. iCM are
currently commercially available for such use. Phar-
macokinetic data are also possible by evaluating
hepatic metabolism in iPSC-derived hepatocytes. To
validate such a notion, Takayma et al. (121) were able
to assess interindividual differences in the hepatic
metabolism and drug response using iPSC-derived
hepatocyte-like cells derived from primary human
hepatocytes of 12 donors. The cytochrome P450
metabolism of iPSC-derived hepatocyte-like cells was
found to correlate highly with the primary human
hepatocytes of origin, with preservation of interin-
dividual differences (121).
Though it remains difﬁcult to model adult-onset
diseases such as atherosclerotic vascular disease
using iPSC, Adams et al. (122) have found that iECdemonstrate functional features that may make
them good candidates for understanding the role of
EC in cardiovascular disease and for testing
EC-based therapies. Speciﬁcally, the investigators
demonstrated that in response to proinﬂammatory
factors, iEC become activated and promote leukocyte
transmigration in vitro. When subjected to ﬂow
dynamics in vitro that are known to promote or
protect against atherosclerosis formation, iEC exhibit
behavior similar to what is seen in human models of
disease with different expression of mechanoregu-
lated genes.
LIMITATIONS TO iPSC-DERIVED DISEASE MODELS. Many
of the above-mentioned challenges for cardiovascular
regeneration are also applicable to iPSC-derived dis-
ease models. Genetic alterations during the reprog-
ramming process, incomplete reprogramming,
changes induced during passages in culture, and
differentiation-induced heterogeneous states of iCM
development, including immature iCM, are limita-
tions of iPSC-derived disease models (123). In addi-
tion, another set of challenges exists that is speciﬁc to
disease modeling. For instance, not all human dis-
eases can be modeled in vitro using iPSC. It is difﬁcult
to recapitulate diseases that depend on complex in-
teractions of multiple genetic and environmental
factors or on a long incubation period, such as
atherosclerosis and congenital heart disease. At the
drug screening level, it is not always possible to
measure all toxicities or side effects at the cellular
level. Investigation of medication-induced mood
changes or long-term side effects in remote tissues
will still need clinical human studies and post-
marketing research. However, advances in bioengi-
neering technologies such as microﬂuidics (124),
high-throughput single-molecule optoﬂuidic analysis
(125), and disease on chip technologies (126,127) are
expected to overcome some of these limitations.
These novel models and experimental constructs will
perfuse drug solutions on iPSC-derivatives, including
hepatic, renal, pulmonary, and cardiac cells in series
or parallel, to simulate the multisystem interactions
within the body and to assess important toxicities
and/or side effects.
SUMMARY AND CONCLUSIONS
iPSC represent a promising tool for cardiovascular
regeneration, disease modeling, and drug discovery.
Despite some encouraging results in pre-clinical
studies using iCM for cardiac regeneration, long-
term engraftment remains challenging and the
long-term results are unclear. It is possible that these
issues may be ameliorated with the use of alternative
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520delivery methods such as iPSC-based patches. Given
the low engraftment and other limitations of iCM,
some of the initial positive pre-clinical results with
iCM should be interpreted with some skepticism.
These studies will require long-term follow-up in pre-
clinical models and eventually phase I clinical trials.
As a new emerging technology, the application of iCM
for the treatment of advanced heart failure is maturing
rapidly by addressing the major extant challenges,
including engraftment, immunogenicity, tumorige-
nicity, and genetic alterations from reprogramming
(42,43). Innovative molecular and bioengineering
techniques to enhance cellular engraftment, reduce
immunogenicity, eliminate tumorigenicity, identify
paracrine factors, and generate mature and homoge-
neous iCM have a great potential to lead to successful
salvage or regeneration of the injured myocar-
dium and permanent restoration of cardiac function.Similarly, although no clinical trials of iPSC for
vascular disease have been initiated, pre-clinical
studies support optimism for this potential applica-
tion. However, a host of issues similar to those that
plague the application of iCM for cardiac regeneration
in heart failure arise in the application of iEC to the
ﬁeld of vascular regeneration. There is still a strong
need to identify novel methods to improve the yield of
iPSC, to enhance production consistency and quality,
and to improve regenerative effects following trans-
plantation into tissues. The ability to model human
disease in a petri dish provides a compelling biomed-
ical rationale to pursue this pioneering research.
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